Chamomile Efficacy in Irritable Bowel Syndrome

Chamomile Efficacy in relief of symptoms of Irritable Bowel Syndrome in Patients with Irritable Bowel Syndrome

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT201106206842N1

Enrollment

Registered

2012-06-27

Start date

2009-09-28

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

irritable bowel syndrome. Irritable bowel syndrome with diarrhoea, Irritable bowel syndrome without diarrhea

Interventions

Intervention 1: 45 patients who fulfilled the ROOM II criteria and had no organic disease enrolled in this study and were asked to take Chamomile 20 drops daily for four weeks. They were asked to fill

Treatment - Other

Treatment - Drugs

45 patients who fulfilled the ROOM II criteria and had no organic disease enrolled in this study and were asked to take Chamomile 20 drops daily for four weeks. They were asked to fill in IBS-associat

a prospective pre-post study in camomile use The drop was produced by Soha Jissa Company Tehran, Iran and contained bizabulol and camazolen (69.47 mg/100cc). The patients used the drop for 4 we

This intervention dont have any control group. This study is a comparing method between before and after camomile use in patients who use camomile.

Eligibility

Sex/Gender

All

Age

10 Years to 60 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: diagnosis of IBS (with diarrhea or constipation dominancy); no history of sensitivity to milk and its products, age between 10 to 50 years; willingness to participate; no other active illness (specially asthma); no drug consumption (specially anticoagulants); no psychiatric illness; not having pregnancy or doing breast feeding; no history of hyper sensitivity; no current therapy for IBS; and no abnormal lab data (CBC/ ESR/ CRP/ TSH). Exclusion criteria: history of sensitivity to milk and its products; other active illnesses(specially asthma); any psychiatric illnesses; history of hypersensitivity; current therapy for IBS; any abnormal lab data(CBC/ESR/CRP/TSH)

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Frequency of bowel habit. Timepoint: every two weeks. Method of measurement: questionare.;Abdominal pain. Timepoint: every two weeks. Method of measurement: questionare.	—

Secondary

Measure	Time frame
Distention. Timepoint: every two weeks. Method of measurement: questionare.	—

Countries

Iran (Islamic Republic of)

Contacts

Public Contactdr Reyhaneh Asadi

Tehran University of Medical Sciences, Medical School

reyhane_asadi@yahoo.com+98 21 6405 3405

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026